Lonza, Cryoport Partner in Cell and Gene Therapy Field

News
Article

Lonza and Cryoport have partnered up to strengthen Lonza’s ‘vein-to-vein’ delivery network by removing supply chain hurdles faced by developers of personalized therapeutics.

Lonza and Cryoport have partnered up to strengthen Lonza’s ‘vein-to-vein’ delivery network by removing supply chain hurdles faced by developers of personalized therapeutics, it was revealed in a Nov. 5, 2019 press release.

As part of the commitment, Lonza has announced that Cryoport is a preferred partner for the transport and delivery of patient tissues globally. Building on the recent partnership between Lonza and Vineti, this new collaboration will aim to provide fully integrated solutions, including co-location of manufacturing bioservices and distribution facilities, automated data management, and process optimization.

“The Lonza-Cryoport collaboration is an enabling part of a wider goal for Lonza to create a network of strategic partnerships and capabilities that enable seamless vein-to-vein delivery of cell and gene therapies for its customers and their patients,” said Alberto Santagostino, SVP head of Cell & Gene Technologies, Lonza Pharma & Biotech, in the press release. “There is no doubt that this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services, allowing us to provide a fully integrated solution that reduces risk and increases transparency.”

“Clinical trial activity in the cell and gene therapy sector is rapidly growing as biopharmaceutical companies discover new ways to harness regenerative therapies and combat illnesses. As more and more of these therapies approach commercialization, there is strengthening demand for reliable, integrated outsourced manufacturing and distribution solutions,” added Jerrell Shelton, CEO, Cryoport. “Our partnership agreement with Lonza, an internationally-renowned supplier to the pharma and biotech markets, will improve effectiveness, efficiency, and safety throughout the cell and gene therapy manufacturing process by integrating our temperature-controlled supply chain solutions with Lonza’s manufacturing services.”

Source: Lonza

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content